en bloc resection involving total penectomy, cystoprostatectomy, resection of the pubic rami and urogenital diaphragm, with pelvic lymphadenectomy. In addition, creating a urinary diversion.
total penectomy involving removal of the penis, urethra, and penile root
partial penectomy involving excision of the malignant lesion with 2-cm margins
transurethral resection or fulguration
A. en bloc resection involving total penectomy, cystoprostatectomy, resection of the pubic rami and urogenital diaphragm, with pelvic lymphadenectomy. In addition, creating a urinary diversion.
epirubicin
mitomycin c
BCG
none of the above
undergo cystectomy
try mitomycin c
take a second course of BCG
take a second course of BCG + quinolones
0.6 - 2%
2 - 6%
6 - 10%
12 - 16%
sensitivity to chemotherapy and age at presentation
anatomic location and extent of the tumor
histologic type of the tumor and sensitivity to radiotherapy
tumors stage and grade
radical cysto-prostatectomy
anterior pelvic exenteration
bilateral pelvic lymphadenectomy
creation of a urinary diversion
RB
cyclin A
HRAS
CD-44
en bloc resection involving total penectomy, cystoprostatectomy, resection of the pubic rami and urogenital diaphragm, with pelvic lymphadenectomy. In addition, creating a urinary diversion.
total penectomy involving removal of the penis, urethra, and penile root
partial penectomy involving excision of the malignant lesion with 2-cm margins
transurethral resection or fulguration
2%
5%
70%
90%
urine cytology
CT urography
cystoscopy
renal function tests
leiomyosarcoma
rhabdosarcoma
carcinosarcoma
neurosarcoma
patients with carcinoma in situ
patients with completely resected solitary tumor
patients with preserved kidney and liver functions after 2 courses of BCG
patients with leiomyosarcoma
irritative bladder symptoms
obstructive bladder symptoms
palpable suprapubic mass on physical examination
painless profuse hematuria
obesity
consuming artificial sweeteners
asbestosis
analgesic abuse
infiltrative proximal penile urethral carcinomas
infiltrative distal penile urethral carcinomas
recurrent proximal penile urethral carcinoma after laser resection
T3/N2/M0 at bulbar urethra
history of pulmonary TB
total incontinence
immunosuppression
impaired renal function
adenocarcinoma
transitional cell carcinoma
squamous cell carcinoma
basal cell carcinoma
cisplatin
BCG
mitomycin C
5-fluorouracil
adenocarcinoma
transitional cell carcinoma
squamous cell carcinoma
basal cell carcinoma
30%
40%
50%
60%
continue the procedure as perforations at this site do no harm
abort the procedure and leave a urethral catheter
convert tumor removal to open method and repair the defect
perform abdominal exploration and manage accordingly
well-differentiated tumor with broad-based invasive font
marked atypia distributed on wide areas of superficial urothelium
atypia is present
no atypia but marked degenerative epithelial changes
10%
20%
30%
40%
frequently found in association with high-grade or extensive TCC
has a rate of progression to muscle invasion of 10-25%
significant areas of CIS are easily missed by routine cystoscopy
treatment begins with TURBT
40 - 55%
55 - 70%
70 - 85%
85 - 100%
multifocality
high tumor grade and advanced stage
presence of CIS
all of the above
single intravesical chemotherapy
TURBT
intravesical BCG vaccine
multiple bladder biopsies
adenocarcinoma
transitional cell carcinoma
squamous cell carcinoma
basal cell carcinoma
2 - 4%
4 - 6%
6 - 8%
8 - 10%
high specificity
high sensitivity
high reliability
strong validity
bladder perforation
obturator nerve reflex
vesico-ureteral reflux
terrible bleeding